Der Onkologe

, Volume 15, Issue 9, pp 844–855 | Cite as

Epidemiologie des Endometriumkarzinoms

Leitthema
  • 55 Downloads

Zusammenfassung

Das Risiko für ein Typ-I-Endometriumkarzinom wird wesentlich durch Faktoren beeinflusst, welche die direkte und/oder indirekte Exposition des Endometriums gegenüber Östrogenen erhöhen. Außerdem sind Polymorphismen im Aromatasegen CYP19A1 und CRP-Gen im Bereich von SNP rs1130864 mit einem erhöhten Risiko assoziiert. Faktoren, die mit erniedrigter Östrogenexposition und erhöhter Gestagenexposition assoziiert sind, erniedrigen das Risiko für Endometriumkarzinom. Gleiches gilt für bestimmte Vitamine, vitamin- und ballastreiche Ernährung sowie Genussmittel wie Kaffee und Tee. Polymorphismen in der 3’-flankierenden Region des Progesteronrezeptors und im SHBG-Gen asp (327) asn (rs 6259) erniedrigen das Risiko. In den Typ-I-Tumoren findet man Mutationen für PTEN, K-RAS, dem β-1-Catenin-Gen CTNNB1 sowie eine Mikrosatelliteninstabilität mit Inaktivierung des Mismatch-Repair-Systems. Im Typ-II-Karzinom sind Mutationen von ERB-B2, PT53, CDKN2A und im E-Cadherin-Gen CDH1 prävalent.

Schlüsselwörter

Endometriumkarzinom Östrogenexposition Genetische Polymorphismen Mutationen 

Epidemiology of endometrial carcinoma

Abstract

An increased risk of endometrial cancer type I is associated with factors which directly or indirectly increase the exposition of the endometrium to estrogens. A higher risk is also associated with polymorphisms in the aromatase gene CYP19A1 and in the CRP gene in the region of SNP rs1130864. Factors which are associated with a low estrogen exposition and a higher gestagen exposition reduce the risk of endometrial cancer. This also applies to certain vitamins, vitamin and ballast-rich nutrition as well as stimulants, such as coffee or tea. Polymorphisms in the 3’ flanking regions of the progesterone receptor and in the SHBG gene asp (327) (rs 6259) lower the risk. In type I tumors mutations in PTEN, KRAS, the β-1-catenin gene CTNNB1 as well as a microsatellite instability with inactivation of the mismatch repair system are found. In type II endometrial cancer mutations in ERB-B2, PT53, CDKN2A and the E-cadherin gene CDH1 are prevalent.

Keywords

Endometrial cancer Estrogen exposition Genetic polymorphisms Mutations 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Amant F, Moerman P, Neven P et al (2005) Endomettrial cancer. Lancet 366(9484):491–505PubMedCrossRefGoogle Scholar
  3. 3.
    Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–559PubMedCrossRefGoogle Scholar
  4. 4.
    Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11(12):1531–1543PubMedGoogle Scholar
  5. 5.
    Parslov M, Lidegaard O, Klintorp S et al (2000) Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 182(1 pt 1):23–29PubMedCrossRefGoogle Scholar
  6. 6.
    Potischman N, Hoover RN, Brinton LA et al (1996) Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88(16):1127–1135PubMedCrossRefGoogle Scholar
  7. 7.
    Zeleniuch-Jacquotte A, Akhmedkhanov A, Kati I et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84(7):975–981PubMedCrossRefGoogle Scholar
  8. 8.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348(17):1625–1638PubMedCrossRefGoogle Scholar
  9. 9.
    Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity and endometrial cancer risk: results from The Netherlands Cohort Study. J Natl Cancer Inst 96(21):1635–1638PubMedCrossRefGoogle Scholar
  10. 10.
    Ayabe T, Tsutsumi O, Sakai H et al (1997) Increased circulating levels of insulin-like grwoth factor-1 and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 44(3):419–424PubMedCrossRefGoogle Scholar
  11. 11.
    Adesanya OO, Zhou J, Samathanam C (1999) Powell-Braxton L, Bondy CA. Insulin-like growth factor 1 is requires for G2 progression in the estradiol-induced mitotic cycle. Proc Natl Acad Sci U S A 96(6):3287–3291PubMedCrossRefGoogle Scholar
  12. 12.
    Gielen SCJP, Hanekamp EE, Blok LJ et al (2005) Steroid-modulated proliferation of human endometrial carcinoma cell lines: any role for insulin-like growth factor signaling? J Soc Gynecol Investig 12(1):58–64PubMedCrossRefGoogle Scholar
  13. 13.
    Lacey JV Jr, Potischman N, Madigan MP et al (2004) Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a US case-control study. Cancer Epidemiol Biomarkers Prev 13(4):607–612PubMedGoogle Scholar
  14. 14.
    Suvanto-Lukkonen E, Sundstrom H, Penttinen J et al (1995) Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 22(3):255–262CrossRefGoogle Scholar
  15. 15.
    Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10(6):611–616PubMedGoogle Scholar
  16. 16.
    Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma (published correction appears in Lancet. 362(93890):1082. Lancet 361(9371):1810–1812PubMedCrossRefGoogle Scholar
  17. 17.
    Colbert LLH, Lacey JV, Schairer C et al (2003) Physical activity and risk of endometrial cancer in a prospective cohort study (United States). Cancer Causes Control 14(6):559–567PubMedCrossRefGoogle Scholar
  18. 18.
    Furberg AS, Thune I (2003) Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort (published correction appears in Int J Cancer 104(6):799. Int J Cancer 104(6):669–676PubMedCrossRefGoogle Scholar
  19. 19.
    McTiernan A, Tworoger SS, Ulrich CM et al (2004) Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 64(8):2923–2928PubMedCrossRefGoogle Scholar
  20. 20.
    Viswanathan AN, Feskanich D, DeVivo I et al (2005) Smoking and the risk of endometrial cancer: results from the Nurses Health Study. Int J Cancer 114(6):996–1001PubMedCrossRefGoogle Scholar
  21. 21.
    Lesko SM, Rosenberg L, Kaufmann DW et al (1985) Cigarette smoking and the risk of endometrial cancer. N Engl J Med 313(10):593–596PubMedGoogle Scholar
  22. 22.
    Klip H, Burger CW, Kenemans P, Van Leeuwen FE (2000) Cancer risk associated with subertility and ovulation inductions: a review. Cancer Causes Control 11(4):319–344PubMedCrossRefGoogle Scholar
  23. 23.
    Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2002) Grand multiparity and incidence of endometrial cancer: a population-bawsed study in Finland. Int J Cancer 98(6):912–915PubMedCrossRefGoogle Scholar
  24. 24.
    Chubak J, Tworoger SS, Yasui Y et al (2004) Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev 13(8):1296–1301PubMedGoogle Scholar
  25. 25.
    Deligeoroglou E, Michailidis E, Creatsas G (2003) Oral contraceptive and reproductive system cancer. Ann N Y Acad Sci 997:199–208PubMedCrossRefGoogle Scholar
  26. 26.
    Anderson GL, Judd HL, Kaunitz AM et al (2003) Woment’s Health Initiative Investigators. Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: the Woment’s Health Initiative randomized trial. JAMA 290(13):1739–1748PubMedCrossRefGoogle Scholar
  27. 27.
    Van Gorp T, Neven P (2002) Endometrial safety of hormone replacement therapy: review of literature. Maturitas 42(2):93–104CrossRefGoogle Scholar
  28. 28.
    Beral V, Bull D, Reeves G, Million Women Study Collaborators (2005) Endometrial cancer and homone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551PubMedCrossRefGoogle Scholar
  29. 29.
    Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935–82. J Natl Cancer Inst Monogr 68:99–112Google Scholar
  30. 30.
    Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17PubMedCrossRefGoogle Scholar
  31. 31.
    Levine RL, Cargile CB, Blazes MS et al (1998) PTEN mutations and microsatellite instability in complex atypical hyperplasia: a precursor lesions to uterine endometroid carcinoma. Cancer Res 58(15):3254–3258PubMedGoogle Scholar
  32. 32.
    Emons G, Fleckenstein G, Hinney B et al (2000) Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7(4):227–242PubMedCrossRefGoogle Scholar
  33. 33.
    Clement PB, Young RH (2002) Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9(3):145–184PubMedCrossRefGoogle Scholar
  34. 34.
    Ambros RA, Sherman ME, Zahn CM et al (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26(11):1260–1267PubMedCrossRefGoogle Scholar
  35. 35.
    Zheng W, Cao P, Zheng M et al (1996) P53 overexpression and bel-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61(2):167–174PubMedCrossRefGoogle Scholar
  36. 36.
    Mutter GL, Lin MC, Fitzgerald JT et al (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92(11):924–930PubMedCrossRefGoogle Scholar
  37. 37.
    Mutter GL, Lin MC, Fitzgerald JT et al (2000) Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85(6):2334–2338PubMedCrossRefGoogle Scholar
  38. 38.
    Mutter GL, Baak JPA, Fitzgerald JT et al (2001) Global expression changes of constructive and hormonally regulated genes durino endometrial neoplastic transformation. Gynecol Oncol 83(2):177–185PubMedCrossRefGoogle Scholar
  39. 39.
    Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PREN/MMAC1 mutations in endometrial cancers. Cancer Res 57(21):4736–4738PubMedGoogle Scholar
  40. 40.
    Lax SF, Kendall B, Tashiro H et al (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824PubMedCrossRefGoogle Scholar
  41. 41.
    Lagarda H, Catasus L, Arguelles R et al (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193(2):193–199PubMedCrossRefGoogle Scholar
  42. 42.
    Enomoto T, Inoue M, Perantoni AO et al (1991) K-ras activation in premalignent and malignant epithelial lesions of the human uterus. Cancer Res 51(19):5308–5314PubMedGoogle Scholar
  43. 43.
    Scholten AN, Creutzberg CL, van den Broek LJ et al (2003) Nuclear beta- catenin is a molecular feature of type 1 endometrial carcinoma. J Pathol 201(3):460–465PubMedCrossRefGoogle Scholar
  44. 44.
    Moreno-Bueno G, Hardisson D, Sanchez C et al (2002) Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21(52):7981–7990PubMedCrossRefGoogle Scholar
  45. 45.
    Mirabelli-Primdahl L, Gryfe R, Kim H et al (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59(14):3346–3351PubMedGoogle Scholar
  46. 46.
    Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444(3):213–223. Epub 2004 Jan 28PubMedCrossRefGoogle Scholar
  47. 47.
    Lax SF, Pizer ES, Ronnett BM, Kurmann RJ (1998) Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression. Hum Pathol 29(6):551–558PubMedCrossRefGoogle Scholar
  48. 48.
    Duggan BD, Felix JC, Muderspach LI et al (1994) Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 86(16):1216–1221PubMedCrossRefGoogle Scholar
  49. 49.
    Mutter GL, Boynton KA, Faquin WC et al (1996) Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 56(19):4483–4486PubMedGoogle Scholar
  50. 50.
    Risinger JI, Berchuck A, Kohler MF et al (1993) Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53(21):5100–5103PubMedGoogle Scholar
  51. 51.
    Gryfe R, Kim H, Hsieh ETK et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342(2):69–77PubMedCrossRefGoogle Scholar
  52. 52.
    Sherman ME, Bur ME, Kurmann RJ (1995) P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26(11):1268–1274PubMedCrossRefGoogle Scholar
  53. 53.
    Peltomaki P, Vasen HF, International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 113(4):1146–1158PubMedCrossRefGoogle Scholar
  54. 54.
    Miyaki M, Konishi M, Tanaka K et al (1997) Germline mutation of MSH6 as a cause of hereditary nonpolyposis colorectal cancer (letter). Nat Genet 17(3):271–272PubMedCrossRefGoogle Scholar
  55. 55.
    Akiyama Y, Sato H, Yamada T et al (1997) Germ-line mutation of the hMSH6/GTPB gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 57(18):3920–3923PubMedGoogle Scholar
  56. 56.
    Kim YB, Holschneider CH, Ghosh K et al (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: report of seven cases and review of the literature. Cancer 79(2):320–327PubMedCrossRefGoogle Scholar
  57. 57.
    Sonoda G, du Manoir S, Godwin AK et al (1997) Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. Genes Chromosomes Cancer 18(2):115–125PubMedCrossRefGoogle Scholar
  58. 58.
    Niederacher D, An HX, Cho YJ et al (1999) Mutations and amplification of oncogenes in endometrial cancer. Oncology 56(1):59–65PubMedCrossRefGoogle Scholar
  59. 59.
    Tashiro H, Isacson C, Levine R et al (1997) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150(1):177–185PubMedGoogle Scholar
  60. 60.
    Goodfellow PJ, Buttin BM, Herzog TJ et al (2003) Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 100(10):5908–5913PubMedCrossRefGoogle Scholar
  61. 61.
    Tashiro H, Lay SF, Gaudin PB et al (1997) Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 150(1):75–79PubMedGoogle Scholar
  62. 62.
    Saffari B, Jones LA, Elnaggar A et al (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55(23):5693–5698PubMedGoogle Scholar
  63. 63.
    Halperin R, Zehavi S, Habler L et al (2001) Comparative immunohistolochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 22(2):122–126PubMedGoogle Scholar
  64. 64.
    Holcomb K, delatore R, Pedemonte B et al (2002) E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 100(6):1290–1295PubMedCrossRefGoogle Scholar
  65. 65.
    Abelere VM, Vergote IB, Kjorstad KE, Trope CG (1996) Clear cell carcinoma of the endometrium: prognosis and metastatic pattern. Cancer 78(8):1740–1747CrossRefGoogle Scholar
  66. 66.
    Wheeler DT, Bell KA, Kurman RJ, Sherman ME (2000) Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 24(6):797–806PubMedCrossRefGoogle Scholar
  67. 67.
    Thomas MB, Mariani A, Cliby WA et al (2007) Role of cytoreduction in state III and IV uterine papillary serous carcinoma. Gynecol Oncol 107(2):190–193. Epub 2007 Sep 6PubMedCrossRefGoogle Scholar
  68. 68.
    Pinol V, Castells A, Andreu M et al (2005) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994PubMedCrossRefGoogle Scholar
  69. 69.
    Karlsson B, Granberg S, Wikland M et al (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding – a Nordic multicenter study. Am J Obstet Gynecol 172(5):1488–1494PubMedCrossRefGoogle Scholar
  70. 70.
    DuBeshter B, Warshal DP, Angel C et al (1991) Endometrial carcinoma: the relevance of cervical cytology. Obstet Gynecol 77(3):458–462PubMedGoogle Scholar
  71. 71.
    Gu M, Shi W, Barakat RR et al (2001) Pap smears in women with endometrial carcinoma. Acta Cytol 45(4):555–560PubMedGoogle Scholar
  72. 72.
    Wright TC Jr, Cox JT, Massad LS et al (2002) 2001 ASCCO-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287(16):2120–2129PubMedCrossRefGoogle Scholar
  73. 73.
    Wu HH, Schuetz MJ III, Cramer H (2001) Significance of benign endometrial cells in Pap smears from postmenopausal women. J Reprod Med 46(9):795–798PubMedGoogle Scholar
  74. 74.
    Langer RD, Piece JJ, O’Hanlan KA et al (1997) Postmenopausal Estrogen/Progestin Interventions Trial. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 337(25):1792–1798PubMedCrossRefGoogle Scholar
  75. 75.
    Naim NM, Mahdy ZA, Ahmad S, Razi ZRM (2007) The Vabra aspirator versus the pipelle device for outpatient endometrial sampling. Aust N Z J Obstet Gynaecol 47(2):132–136PubMedCrossRefGoogle Scholar
  76. 76.
    Del Priore G, Wiliams R, Harbatkin CB et al (2001) Endometrial brush biopsy for the diagnosis of endometrial cancer. J Reprod Med 46(5):439–443Google Scholar
  77. 77.
    Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP (2000) The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89(8):1765–1772PubMedCrossRefGoogle Scholar
  78. 78.
    Epstein E, Skoog L, Valentin L (2001) Comparison of Endorette and dilatation and curettage for sampling of the endometrium in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 80(10):959–964PubMedGoogle Scholar
  79. 79.
    Dubinsky TJ (2004) Value of sonography in the diagnosis of abnormal vaginal bleeding. J Clin Ultrasound 32(7):348–353PubMedCrossRefGoogle Scholar
  80. 80.
    Minagawa Y, Sato S, Ito M et al (2005) Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer. Gynecol Obstet Invest 59(3):149–154. Epub 2005 Jan 3PubMedCrossRefGoogle Scholar
  81. 81.
    Kidokoro K, Ino K, Hirose K (2009) Association between CYP19A1 polymorphisms and sex hormone in postmenopausal Japanese women, J Hum Genet 54(2):78–85Google Scholar
  82. 82.
    Xu WH, Long JR, Zheng A et al (2009) Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population. CancerGoogle Scholar
  83. 83.
    Yang HP, Garcia-Closas M, Lacey JV Jr (2009) Genetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 18(2):585–589PubMedCrossRefGoogle Scholar
  84. 84.
    Wright JD, Fiorelli J, Schiff PB et al (2009) Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 115(6):1276–1285PubMedCrossRefGoogle Scholar
  85. 85.
    Kumar S, Shah JP, Bryant CS et al (2009) Radiation-associated endometrial cancer. Obstet Gynecol 113:319–325PubMedGoogle Scholar
  86. 86.
    Williams MG, Bandera EV, Demissie K, Rodriguez-Rodriguez L (2009) Synchronus primary ovarian and endometrial: a population-based assessment of survival. Obstet Gynecol 113(4):783–789PubMedGoogle Scholar
  87. 87.
    Danforth KN, Gierach GL, Brinton LA et al (2009) Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res (Phila Pa) 2(5):466–472CrossRefGoogle Scholar
  88. 88.
    Reed SD, Newton KM, Clinton WL et al (2009) Incidence of endometrial hyperplasia. Am J Obstet GynecolGoogle Scholar
  89. 89.
    McGrath M, Lepine J, Lee IM et al (2009) De Vivo I: Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genomics 19(3):239–243PubMedCrossRefGoogle Scholar
  90. 90.
    Lacey JV Jr, Chia VM (2009) Endometrial hyperplasie and the risk of progression to carcinoma. Maturitas 63(81):39–44PubMedCrossRefGoogle Scholar
  91. 91.
    Barrow E, Robinson L, Alduaij W et al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75(2):141–149PubMedCrossRefGoogle Scholar
  92. 92.
    Einarsdóttir K, Darabi H, Czene K et al (2009) Common genetic variability in ESR1 und EGF in relation to endometrial cancer risk and survival. Br J Cancer 100(8):1358–1364PubMedCrossRefGoogle Scholar
  93. 93.
    Mylonas I, Worbs S, Shabani N et al (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and –betaB subunits in 302 cases. Eur J Cancer 45(7):1304–1314PubMedCrossRefGoogle Scholar
  94. 94.
    Lee L, Garrett L, Lee H et al (2009) Association of clear cell carcinoma of the Endometrium with a high rate of venous thromboembolism. J Reprod Med 54(3):133–138PubMedGoogle Scholar
  95. 95.
    Friberg E, Wolk A (2009) Long-term alcohol consumption and risk of endometrial cancer incidence: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 18(1):355–358PubMedCrossRefGoogle Scholar
  96. 96.
    Setiawan VW, Doherty JA, Shu XO et al (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242–247PubMedCrossRefGoogle Scholar
  97. 97.
    Gierach GL, Chang SC, Brinton LA et al (2009) Physical activity, sedentary behavoir, and endometrial cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 124(9):2139–2147PubMedCrossRefGoogle Scholar
  98. 98.
    McCann SE, Yeh M, Rodabaugh K, Moysich KB (2009) Higher regular coffee and tea consumption is associated with reduced endometrial cancer risk. Int J Cancer 124(7):1650–1653PubMedCrossRefGoogle Scholar
  99. 99.
    Bravi F, Scotti L, Bosetti C et al (2009) Food groups and endometrial cancer risk: a case-control study from Italy. Am J Obstet Gynecol 200(3):293.e1–293.e7PubMedGoogle Scholar
  100. 100.
    Konecny GE, Santos L, Winterhoff B et al (2009) HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 100(1):89–95PubMedCrossRefGoogle Scholar
  101. 101.
    Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16(1):53–56PubMedGoogle Scholar
  102. 102.
    Yeh M, Moysich KB, Jayaprakash V et al (2009) Higher intakes of vegetables and vegetable-related nutrients are associated with lower endometrial cancer risks. J Nutr 139(2):317–322PubMedGoogle Scholar
  103. 103.
    Larsson SC, Hákansson N, Akesson A, Wolk A (2009) Long-term dietary acrylamide intake and risk of endometrial cancer in a prospective cohort of Swedish women. Int J Cancer 124(5):1196–1199PubMedCrossRefGoogle Scholar
  104. 104.
    Xu WH, Zheng W, Cai Q et al (2008) The Asp (327) Asn polymorphism in he sex hormone-binding globulin gene modifies the association of soy food and tea intake with endometrial cancer risk. Nutr Cancer 60(6):736–743PubMedCrossRefGoogle Scholar
  105. 105.
    Pennant S, Manek S, Kehoe S (2008) Endometrial atypical hyperplasia and subsequent diagnosis of endometrial cancer: a retrospective audit and literature review. J Obstet Gynaecol 28(6):632–633PubMedCrossRefGoogle Scholar
  106. 106.
    Albrektsen G, Heuch I, Thoresen S, Kvale G (2008) Twin birth, sex of children and maternal risk of endometrial cancer: a cohort study in Norway. Acta Obstet Gynecol Scand 87(11):1123–1128PubMedCrossRefGoogle Scholar
  107. 107.
    FaderAN, Arriba LN, Frasure HE, von Gruenigen VE (2009) Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol OncolGoogle Scholar
  108. 108.
    Soliman PT, Bassett RL Jr, Wilson EB et al (2008) Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol 112(4):835–842PubMedGoogle Scholar
  109. 109.
    Satoh T, Matsumoto K, Uno K et al (2008) Silent venous thromboembolism before treatment in endometrial cancer and the risk factors. Br J Cancer 99(7):1034–1039PubMedCrossRefGoogle Scholar
  110. 110.
    DeMichele A, Troxel AB, Berlin JA et al (2008) Impact of raloxifen or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 26(25):4151–4159PubMedCrossRefGoogle Scholar
  111. 111.
    Shimazu T, Inoue M, Sasazuki S et al (2008) Coffee consumption and risk of endometrial cancer: a prospective study in Japan. Int J Cancer 123(810):2406–2410PubMedCrossRefGoogle Scholar
  112. 112.
    Nagle CM, Olsen CM, Webb PM et al (2008) Endometroid and clear cell ovarian cancers: a comperative analysis of risk facots. Eur J Cancer 44(16):2477–2484PubMedCrossRefGoogle Scholar
  113. 113.
    Maxwell GL, Tian C, Risinger JI et al (2008) Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer 113(6):1431–1437PubMedCrossRefGoogle Scholar
  114. 114.
    Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68(7):2507–2513PubMedCrossRefGoogle Scholar
  115. 115.
    Hosono S, Matsuo K, Kajiyama H et al (2008) Reduced risk of endometrial cancer from alcohol drinking in Japanese. Cancer Sci 99(6):1195–1201PubMedCrossRefGoogle Scholar
  116. 116.
    Pelucchi C, Dal Maso L, Montella M et al (2008) Dietary intake of carotenoids and retinol and endometrial cancer risk in a Italian case-control study. Cancer Causes Control 19(10):1209–1215PubMedCrossRefGoogle Scholar
  117. 117.
    Koizumi T, Nakaya N, Okamura C et al (2008) Case-control study of coffee consumption and the risk of endometrial endometrioid adenocarcinoma. Eur J Cancer Prev 17(4):358–363PubMedCrossRefGoogle Scholar
  118. 118.
    Xue F, Hilakivi-Clarke LA, Maxwell GL et al (2008) Infant feeding and the incidence of endometrial cancer. Cancer Epidemiol Biomarkers Prev 17(6):1316–1321PubMedCrossRefGoogle Scholar
  119. 119.
    Patel AV, Feigelson HS, Talbot JT et al (2008) The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 123(8):1877–1882PubMedCrossRefGoogle Scholar
  120. 120.
    Walsh MD, Cummings MC, Buchanan DD et al (2008) Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 14(6):1692–1700PubMedCrossRefGoogle Scholar
  121. 121.
    Lacey JV Jr, Mutter GL, Ronnett BM et al (2008) PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 68(14):6014–6020PubMedCrossRefGoogle Scholar
  122. 122.
    Olson SH, Orlow I, Bayuga S et al (2008) Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 19(9):955–963PubMedGoogle Scholar
  123. 123.
    Engelsen IB, Stefansson IM, Aksien LA, Salvesen HB (2008) GATA 3 expression in estrogen receptor alpha-negative endometrial carcinoma identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199(5):543.e1–543.e7PubMedCrossRefGoogle Scholar
  124. 124.
    Wen W, Cai Q, Xian YB et al (2008) The modifying effect of C-reactive protein gene polymorphisms on the association between central obesity and endometrial cancer risk. Cancer 112(11):2409–2416PubMedCrossRefGoogle Scholar
  125. 125.
    Robert-Koch-Institut, KrebsregisterGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Klinik für Gynäkologie u. Brustzentrum Charité Campus Benjamin Franklin und Charité Campus MitteBerlinDeutschland

Personalised recommendations